scholarly journals Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons

2015 ◽  
Vol 11 (2) ◽  
pp. 386-390 ◽  
Author(s):  
Satoshi Hiroi ◽  
Saeko Morikawa ◽  
Keiko Nakata ◽  
Akiko Maeda ◽  
Tsuneji Kanno ◽  
...  
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Trivalent Influenza Vaccine

scholarly journals Immunoglobulin G, A and M response to influenza vaccination in different age groups: effects of priming and boosting

1986 ◽  
Vol 96 (3) ◽  
pp. 513-522 ◽  
Author(s):  
Walter E. P. Beyer ◽  
Jos T. M. Van Der Logt ◽  
Ruud van Beek ◽  
Nic Masurel
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Influenza Infection ◽  
Age Groups ◽  
Antibody Responses ◽  
Trivalent Influenza Vaccine ◽  
Antibody Capture ◽  
The Mean ◽  
Original Antigenic Sin

SUMMARYFifty volunteers, treated with an inactivated trivalent influenza vaccine containing A/Bangkok/1/79 (H3N2), A/Brazil/11/78 (H1N1) and B/Singapore/222/79 virus, were subdivided according to the estimated first exposure to influenza in their lifetime (priming) and the presence of antibodies against the vaccine components in the pre-vaccination sera. The isotypic antibody response (IgG, IgA, IgM) was determined by means of an antibody capture haemadsorption immunosorbent technique. For all three vaccine components, previously seropositive subjects produced antibodies of the IgG- and IgA-class more frequently than previously seronegative persons. Subjects primed to one of the influenza A subtypes showed more IgG and IgA responses in comparison with those unprimed (prime-effect). In contrast, IgM antibodies occurred in only 19 and 11% of primed, but in 59 and 54% of unprimed subjects, for A (H3N2) and A (HlNl), respectively. The incidence of IgM titre rises was not influenced by the prevaccination state. However, the mean magnitude of anti-A(H1N1)-IgM titre rises was greater in those previously seronegative. The concepts of primary and reinfection and of ‘original antigenic sin’ are discussed, and it is suggested that age and, if possible, serological state prior to antigen-exposure should be taken into account when studying isotypic antibody responses after influenza infection or vaccination.

scholarly journals Vaccine effectiveness for influenza in the elderly in welfare nursing homes during an influenza A (H3N2) epidemic

2000 ◽  
Vol 125 (2) ◽  
pp. 393-397 ◽  
Author(s):  
Y. DEGUCHI ◽  
Y. TAKASUGI ◽  
K. NISHIMURA
Keyword(s):  
Nursing Homes ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Hospital Admissions ◽  
Influenza Virus Infection ◽  
Severe Infection ◽  
The Elderly ◽  
Trivalent Influenza Vaccine ◽  
Homes For The Elderly ◽  
Vaccine Effect

Influenza vaccine effect on the occurrence and severity of influenza virus infection in a population residing in nursing homes for the elderly was studied as a cohort study during an influenza A (H3N2) epidemic in Japan. Of 22462 individuals living in 301 welfare nursing homes, 10739 voluntarily received inactivated, sub-unit trivalent influenza vaccine in a programme supported by the Osaka Prefectural Government. There were statistically significantly fewer cases of influenza, hospital admissions due to severe infection, and deaths due to influenza in the vaccinated cohort compared to the unvaccinated controls. No serious adverse reactions to vaccination were recorded. Thus influenza vaccination is effective for preventing influenza disease in persons aged 65 years and over, and should be an integral part of the care of this population residing in nursing homes.

Influenza A Virus Aboard a US Navy Ship in 1972 and the Antibody Response of the Crew to Influenza Vaccine

1975 ◽  
Vol 140 (3) ◽  
pp. 179-181 ◽  
Author(s):  
Irving J. Green ◽  
George S. Irving ◽  
Shao-chen Hung ◽  
James V. Davenport
Keyword(s):  
Antibody Response ◽  
Influenza Vaccine ◽  
Influenza A Virus ◽  
Influenza A ◽  
Us Navy

scholarly journals Immunogenicity of a Monovalent Pandemic Influenza A H1N1 Virus Vaccine with or without Prior Seasonal Influenza Vaccine Administration

2012 ◽  
Vol 19 (10) ◽  
pp. 1690-1692 ◽  
Author(s):  
Hidetoshi Igari ◽  
Akira Watanabe ◽  
Shunsuke Segawa ◽  
Akiko Suzuki ◽  
Mariko Watanabe ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Virus ◽  
Geometric Mean ◽  
Vaccine Administration ◽  
Trivalent Influenza Vaccine ◽  
Influenza A H1n1 ◽  
Significant Difference ◽  
Antibody Titers

ABSTRACTThe immunogenicity of pandemic influenza A H1N1 virus (A/H1pdm) vaccine might be modified by prior seasonal trivalent influenza vaccine (sTIV) administration. We conducted a retrospective analysis of immunogenicity of 243 health care workers (number of sTIV-positive [sTIV+] subjects, 216; number of sTIV−subjects, 27) by hemagglutination inhibition. There was no significant difference in the ratios of antibody titers of ≥40 (41.2% versus 48.1%;P= 0.49) and fold increases in geometric mean titer (3.8 versus 4.5;P= 0.37). sTIV injected 7 to 10 days prior to A/H1pdm vaccine administration did not interfere with the immunogenicity of the latter.

scholarly journals Response to influenza vaccine in adjuvant 65-4

1975 ◽  
Vol 74 (2) ◽  
pp. 251-259 ◽  
Author(s):  
J. W. G. Smith ◽  
W. B. Fletcher ◽  
Martin Peters ◽  
M. Westwood ◽  
F. J. Perkins
Keyword(s):  
Single Dose ◽  
Antibody Response ◽  
Influenza Vaccine ◽  
Injection Site ◽  
Influenza A ◽  
Aqueous Suspension ◽  
Geometric Mean ◽  
Antibody Titres ◽  
Adjuvant Vaccine ◽  
Systemic Symptoms

SUMMARYA comparison was made of the antibody response and subjective reactions to zonally-purified influenza vaccine in aqueous suspension and in peanut oil adjuvant 65-4. Both preparations contained 700 CCA units of A/Aichi/2/68, and 300 CCA units of B/Mass/1/71.Subjective reactions were recorded by asking the volunteers to complete a record daily for 5 days. Pain at the injection site was recorded by 64% of the recipients of the oil adjuvant vaccine compared with 35% of the aqueous recipients, but local redness was more frequent after aqueous vaccine. Systemic symptoms were recorded a little more frequently after aqueous than oil adjuvant vaccine.When measured 7½ weeks after a single dose of vaccine, the HAI geometric mean antibody titre (G.M.T.) to the A/Hong Kong/1/68 antigen (antigenically similar to the A/Aichi/2/68 antigen in the vaccine) increased 2·7-fold after aqueous and 16·4-fold after adjuvant vaccine. Sixty-two weeks after vaccination the antibody titres remained higher in those given adjuvant vaccine. The G.M.T. to B/Mass/1/71 increased 1·9-fold 7½ weeks after aqueous vaccine and 3·7-fold after adjuvant vaccine.The antibody response to both influenza A and B antigens was broader in the recipients of adjuvant vaccine. The G.M.T. to A/England/42/72 increased 2·8-fold after aqueous and 13-fold after adjuvant vaccine; and to B/England/847/73 it increased 1·3-fold after aqueous and 1·9-fold after adjuvant vaccine.

scholarly journals Protection by a polyvalent influenza vaccine and persistence of homologous and heterologous HI antibodies during a period of two epidemic seasons

1980 ◽  
Vol 84 (2) ◽  
pp. 237-245 ◽  
Author(s):  
R. Pyhälä
Keyword(s):  
General Population ◽  
Antibody Response ◽  
Influenza Vaccine ◽  
Influenza A ◽  
Geometric Mean ◽  
Influenza B ◽  
Trial Period ◽  
Serum Samples ◽  
Antibody Titres ◽  
The Individual

SUMMARYA split-product influenza A vaccine which contained an influenza B strain (B/Hong Kong/8/73) and two influenza A strains, antigenically identical with A/Fort Dix/741/76 (HswlNl) and A/Victoria/3/75 (H3N2), was offered to personnel of the CPHL. Changes in the antibody status were followed with serum samples collected from 153 participants on the day of vaccination and 1, 13 and 18 months thereafter. During the two epidemic seasons in the trial period there were only four serological influenza A infections (2·6%) among the vaccinees. This is one eighth of the corresponding infection rate (22%) in the general population estimated on the basis of other indices.The vaccinees' antibody response was strongly influenced by the age of the individual subjects. During the trial period the decrease in the antibody titres slowed down. The geometric mean titres of homologous HI antibodies were still substantially higher at the end of the period than at the beginning. This also applied to heterologous antibodies against H1N1 viruses in persons born between 1926 and 1952. In participants born after 1952, the vaccine was not able to evoke these antibodies, and in participants born in or before 1925 the boosting effect was poor.

Sign in / Sign up

Export Citation Format

Share Document